The incidence of nephrogenic systemic fibrosis (NSF) in the U.S. following administration of gadolinium-based contrast agents is falling as healthcare providers restrict the use of MRI contrast in at-risk patient populations, according to an advisory panel meeting convened on Tuesday to discuss U.S. Food and Drug Administration regulation of the products.
FDA panel: NSF incidence falls with gadolinium restrictions
Dec 8, 2009
Latest in MRI
What are the effects of COVID-19 pneumonia after 5 years?
September 24, 2026
Podcast: OSHA report reveals more about 2023 MRI accident
September 22, 2026
Ex-NFL QB Matt Hasselback points brain imaging study
September 21, 2026


.fFmgij6Hin.png?auto=compress%2Cformat&fit=crop&h=100&q=70&w=100)


.fFmgij6Hin.png?auto=compress%2Cformat&fit=crop&h=167&q=70&w=250)











